JOSÉ LUIS
CABRIADA NUÑO
Ikertzailea 2022-(e)ra arte
Hospital Clínico San Carlos de Madrid
Madrid, EspañaHospital Clínico San Carlos de Madrid -ko ikertzaileekin lankidetzan egindako argitalpenak (19)
2023
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
2022
-
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
Biomedicines, Vol. 10, Núm. 3
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
Journal of Clinical Medicine, Vol. 11, Núm. 13
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
2020
-
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596
2019
-
Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients
Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854
-
Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU
Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428
-
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
Therapeutic Advances in Gastroenterology, Vol. 12
2018
-
Addition of granulocyte/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A Randomized multicentre clinical trial
Journal of Crohn's and Colitis, Vol. 12, Núm. 6, pp. 687-694
-
Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
-
Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease
Journal of Crohn's and Colitis, Vol. 11, Núm. 7, pp. 792-800
2016
2014
-
Risk of colectomy in patients with ulcerative colitis under thiopurine treatment
Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293
2013
-
Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era
Alimentary Pharmacology and Therapeutics, Vol. 38, Núm. 7, pp. 752-760
2012
-
Long-term durability of response to adalimumab in Crohn's disease
Inflammatory Bowel Diseases, Vol. 18, Núm. 4, pp. 685-690
2008
-
Recomendaciones de actuación en pacientes con enfermedad de Crohn que empiezan tratamiento con adalimumab: Una guía rápida
Gastroenterologia y Hepatologia, Vol. 31, Núm. 10, pp. 693-697
-
Small-bowel neoplasms in patients undergoing video capsule endoscopy: A multicenter European study
Endoscopy, Vol. 40, Núm. 6, pp. 488-495